G1 Therapeutics' GAAP loss for 6 months of 2022 was $88.638 million, up 34.6% from $65.864 million in the prior year. Revenue decreased 16.1% to $17.475 million from $20.822 million a year earlier.
G1 Therapeutics' GAAP loss for 6 months of 2022 was $88.638 million, up 34.6% from $65.864 million in the prior year. Revenue decreased 16.1% to $17.475 million from $20.822 million a year earlier. 
investor.g1therapeutics.com
English (US) 